Testosterone for Women: What It Is Prescribed For, What the Evidence Supports and What It Does Not

A reader wrote to us last month with a screenshot from a group chat. Four friends in their late forties, one video clip of a wellness influencer holding a small pump bottle, and a single question underneath: “Should we all be on this?” The clip promised more energy, a sharper mind, leaner arms and a libido “like your twenties.” It had several million views.

That is why testosterone for women is trending right now. As of September 2026, short-form videos and podcast episodes are driving a wave of requests to menopause and primary-care clinics, while the regulatory picture has barely moved in years: there is still no testosterone product approved by the FDA for women, and prescribing in the US remains off-label. Meanwhile the strongest research we have, a 2019 global consensus statement and the trials behind it, tells a much narrower story than the videos do.

So we read the trials, checked the guidance and asked the boring but essential question. What does testosterone actually do for women, and what does it not?

What does testosterone do in a woman's body?

Testosterone is often filed under “male hormone,” which is a little like calling insulin a “pancreas hormone” and ignoring that every cell needs it. Women make testosterone throughout life. Before menopause, roughly a quarter comes from the ovaries, a quarter from the adrenal glands (small glands sitting on top of each kidney), and about half is converted in fat, muscle and skin from weaker precursor hormones such as DHEA.

In women it acts on bone, muscle, skin, the brain and sexual tissues, and it is also the raw material the body converts into estrogen. That last point matters: some of what testosterone “does” in a woman is actually estrogen’s work after conversion.

Levels peak in a woman’s twenties and drift downward slowly across adulthood. By the late fifties, the total amount circulating is roughly half of what it was at 25. The natural menopause transition itself does not cause a sudden drop; the decline is gradual and age-related. Surgical removal of both ovaries (a bilateral oophorectomy) is different. That removes a major source overnight, and testosterone can fall by about half within days.

Two other terms come up constantly in this debate. Free testosterone is the small fraction, usually 1 to 2 percent, not bound to carrier proteins and therefore available to tissues. Sex hormone-binding globulin (SHBG) is the main carrier protein; when SHBG rises, for example with oral estrogen or oral contraceptives, free testosterone falls even if the total does not.

This is the biology behind a genuine clinical question. Since testosterone acts on so many tissues, it is reasonable to ask whether replacing the age-related decline would help. The honest answer, as the rest of this piece shows, is that the trials have tested that idea carefully for one outcome and barely at all for the others.

What changed recently, and why testosterone for women is trending

Nothing dramatic has happened to the science in the last year. What has changed is the volume of the conversation and the mismatch between viral claims and the published evidence.

The anchor document is still the Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in September 2019 and endorsed by more than a dozen international endocrine and menopause societies. It concluded that the only evidence-based indication is hypoactive sexual desire disorder (HSDD) in postmenopausal women, after a thorough assessment of other causes. It also stated plainly that there is insufficient evidence to recommend testosterone for cognition, mood, general wellbeing, bone or muscle, and that safety data beyond about two years are lacking.

In the United Kingdom, national menopause guidance has for several years allowed clinicians to consider testosterone for menopausal women with low sexual desire when estrogen-based hormone replacement therapy (HRT) alone has not helped. The NHS describes the same approach on its HRT information pages. The products used are gels licensed for men, applied at a fraction of the male amount and prescribed off-label, meaning outside the licensed indication.

In the United States, as of September 2026, the FDA has not approved any testosterone product for women. A testosterone patch for women was approved in the European Union in 2006 and withdrawn from the market in 2012 for commercial reasons, not new safety findings. A gel developed for women did not meet its efficacy targets in trials completed in 2011. Australia remains the one country with a testosterone cream specifically licensed for postmenopausal women.

Against that quiet regulatory backdrop, social media has filled the gap. Clinics report a rise in women arriving with a level printed from an online lab and a list of symptoms from a video. The trend, in other words, is cultural rather than scientific, which is exactly why the evidence deserves a careful, unhurried look.

What is testosterone for women actually prescribed for?

Strip away the marketing and the list is short. Testosterone for women has one indication supported by randomized trials: hypoactive sexual desire disorder in postmenopausal women.

HSDD is the medical term for a persistent lack of sexual desire that causes personal distress, and that is not better explained by another cause. The distress part is essential. Low interest in sex that does not bother a woman is not a disorder, and guidelines are explicit that treatment is for the distress, not for a number.

The “other causes” clause does most of the work in practice. Before testosterone is considered, a clinician is expected to look at:

• Vaginal dryness and pain with sex, which are far more common after menopause and respond to local estrogen or moisturizers.
• Depression, anxiety and chronic sleep loss, all of which suppress desire.
• Medicines, especially some antidepressants, blood pressure drugs and hormonal contraceptives.
• Relationship strain, a partner’s sexual difficulties and life stress.
• Thyroid disease, iron deficiency and other general conditions.

When those have been addressed and distressing low desire persists, the consensus position supports a trial of testosterone at an amount intended to bring blood levels back to the range typical of premenopausal women, with a review after a few months and stopping if there is no benefit.

What it is not prescribed for, on current evidence, is equally important. Testosterone is not a treatment for hot flashes, night sweats, fatigue, weight gain, low mood, brain fog, hair thinning, or osteoporosis in women. Some of those symptoms improve in trial participants, but not more than in the placebo groups, or the studies were too small to tell.

Premenopausal women are a separate category. The consensus statement found insufficient data to recommend testosterone for women who still have menstrual cycles, and two non-hormonal medicines approved in the US for premenopausal low desire are the options usually discussed instead. Whether any of this applies to an individual is a decision for the treating clinician.

What are the signs of low testosterone in females?

Here is the uncomfortable truth behind every “10 signs of low testosterone in women” listicle: there is no validated set of symptoms, and no agreed blood level, that defines testosterone deficiency in women. The 2019 consensus statement said so directly. That does not mean women’s symptoms are imaginary. It means the symptoms usually attributed to low testosterone overlap almost completely with the symptoms of menopause, sleep deprivation, depression, iron deficiency, thyroid problems and ordinary midlife load.

The features most often mentioned include reduced sexual desire and arousal, fewer or less intense orgasms, low energy, low mood, poor concentration and reduced muscle strength. Each of those has at least three plausible causes unrelated to testosterone. Fatigue in a 49-year-old waking three times a night with hot flashes is far more likely to be about sleep and estrogen than about androgen levels.

What the research does show is a link between testosterone and sexual function specifically. In large observational studies, women with lower testosterone report somewhat lower desire on average, but the overlap between groups is enormous. Plenty of women with low measured levels have a robust sex drive; plenty with mid-range levels do not. Observational data of this kind can show association, not cause, and it cannot tell an individual woman what her level means.

There is one situation where a genuine deficiency state is more likely: women who have had both ovaries removed, or whose ovaries have stopped working early because of chemotherapy, radiation or a genetic condition. Their testosterone falls sharply rather than gradually, and the trials showing benefit for sexual desire were, in part, conducted in surgically menopausal women.

If you recognize yourself in the symptom lists, the useful takeaway is not “I need testosterone” but “I should have these symptoms properly assessed.” A good assessment starts with sleep, mood, medications, relationship factors and menopausal status, and only then asks whether a hormone might be part of the picture.

Can a blood test diagnose low testosterone in women?

Short answer: no, not in the way the online lab menus imply. A longer answer explains why the number on your printout is less informative than it looks.

Testosterone in women circulates at roughly a tenth of male concentrations. Most laboratory assays were designed and calibrated for men, and at the low end of the scale they become imprecise; two labs testing the same sample can return noticeably different results. Levels also swing across the day, peaking in the morning, and shift with the menstrual cycle in women who still have periods. MedlinePlus notes that a testosterone test is generally interpreted alongside symptoms and other hormone results, not on its own.

The 2019 consensus statement drew a firm line: a blood testosterone level should not be used to diagnose HSDD, because no cutoff separates women with the condition from women without it. The diagnosis is clinical, made through a conversation about desire, distress and other causes.

So why test at all? Guidelines suggest a baseline measurement for two reasons. First, to make sure a level is not already high, which would argue against treatment and might point to another condition such as polycystic ovary syndrome. Second, to have a reference point for monitoring, so that a clinician can check a few weeks into treatment that the level has not risen above the premenopausal range. In that role the test is a safety tool, not a diagnostic one.

Free testosterone and SHBG are sometimes added. They help interpret the total, particularly in women taking oral estrogen, which raises SHBG and lowers the free fraction. They do not change the fundamental point that the number does not equal the diagnosis.

If you have already paid for a panel and it says “low,” bring it to your clinician, but expect the conversation to be about how you feel and what else could explain it, not about the digits. That is not dismissiveness. It is what the evidence supports.

What the evidence actually says, graded by strength

Medical evidence comes in tiers. At the top sit randomized controlled trials (RCTs), where participants are assigned by chance to treatment or placebo, and pooled analyses of many such trials. Below them are observational studies, which follow people without assigning treatment and can show patterns but not cause. At the base is expert opinion, which is valuable for filling gaps but is not proof. Here is how testosterone for women sorts into those tiers.

Strong (multiple RCTs, pooled analysis). Sexual desire, arousal, orgasm and the number of satisfying sexual events in postmenopausal women with HSDD. A 2019 systematic review pooling 36 randomized trials with more than 8,000 participants found consistent, statistically significant improvements across these measures, with the effect sizes described as modest. Non-oral routes (gel, cream, patch) were preferred because oral testosterone worsened cholesterol profiles in the trials.

Moderate to weak (small or short trials, mixed results). Mood and wellbeing scores, where a few trials showed small gains and most did not separate from placebo. Bone density, where short trials hint at effects but none were designed or long enough to measure fractures.

Insufficient (observational data or expert opinion only). Memory and cognition, muscle strength and body composition, energy and fatigue, and any use in premenopausal women. The consensus statement explicitly declined to recommend testosterone for any of these.

Unknown (no adequate data). Long-term safety. Trials rarely exceeded two years. Breast cancer risk, cardiovascular outcomes and effects beyond 24 months cannot be judged from current randomized evidence, and women with a history of breast cancer were excluded from the trials.

Read that list again and notice the shape. Testosterone for women rests on one well-supported indication surrounded by a wide ring of hope. That is not a criticism of the hormone. It is simply where the research stands, and honest guidance follows the evidence rather than the enthusiasm.

How much does testosterone therapy for women help libido?

“Modest” is a word that hides a lot, so let us put numbers to it.

The largest trials, run in the mid-2000s with a transdermal patch in postmenopausal women with HSDD, counted “satisfying sexual events” in monthly diaries. Women on testosterone reported on average about one to two additional satisfying events per month compared with roughly one additional event in the placebo groups. The net difference attributable to testosterone was therefore around one event per month. Desire scores on validated questionnaires rose by a small but measurable amount, and distress about sex fell.

Two things about those results deserve emphasis. First, the placebo response was large. Simply entering a study about sexual desire, keeping a diary and talking about sex with a clinician improved matters for many women. Second, the testosterone effect was real and reproducible across trials, which is why every major society accepts the indication.

Who benefited most? Women who had reached menopause naturally and those who had surgical menopause both responded. Women already using estrogen and women not using it both showed gains, though the consensus statement notes the evidence is stronger for women on estrogen. Age, relationship duration and baseline desire did not predict response well, which means there is no reliable way to know in advance who will notice a difference.

Timing matters for expectations. Trials typically saw separation from placebo by about 12 weeks, and guidance suggests reviewing at three to six months and stopping if there is no meaningful improvement. Continuing in the hope that year two will succeed where year one did not is not supported.

It is also worth naming what libido gains did not come with. Trials did not show improved relationship satisfaction as a distinct outcome, and they did not show benefits in women whose low desire was driven by pain, depression or a partner’s difficulties. The hormone addresses one input to a complicated system. For the right woman, one more satisfying encounter a month can matter a great deal. For another, it may not be worth the side effects. That judgment belongs to her and her clinician.

Does testosterone help energy, mood, brain fog or bones?

These are the claims that sell the videos, and they are the claims with the least behind them.

Energy and fatigue. No randomized trial in women has shown testosterone improves fatigue as a primary outcome. Some libido trials included vitality subscales on quality-of-life questionnaires; the changes were small and usually not different from placebo. Fatigue in midlife women is far more strongly linked to disrupted sleep from hot flashes, iron deficiency, thyroid disease and depression. Each of those has effective, evidence-based treatments that do not involve androgens.

Mood. A handful of small trials measured mood and wellbeing. Results were mixed and the studies were short. The consensus statement concluded the evidence is insufficient. Testosterone is not a treatment for depression or anxiety in women, and it should not delay assessment for those conditions.

Brain fog and memory. This is where the gap between claim and data is widest. Observational studies show inconsistent associations between testosterone levels and cognitive scores in older women, some positive, some null, one or two negative. A few small trials of a few months found no convincing cognitive benefit. Menopausal brain fog is real, is often tied to sleep and hot flashes, and generally improves over time. There is no randomized evidence that testosterone treats it.

Bone. Testosterone has plausible effects on bone in laboratory and animal studies, and two-year trials in women found small increases in bone density. None measured fractures, which is the outcome that matters, and none were large enough to weigh benefit against risk. Established treatments for osteoporosis have fracture data; testosterone does not.

Why does this matter beyond accuracy? Because a woman who starts testosterone for energy and feels no better may conclude she needs more, when the trials suggest the problem was never testosterone. Meanwhile the actual cause goes unaddressed. The evidence-first approach is not about withholding a hormone. It is about not letting a plausible story replace a proper diagnosis.

Will testosterone make a woman lose weight?

This question ranks near the top of what people ask search engines about testosterone for women, and the trial data give an answer most videos skip.

In the 2019 pooled analysis of randomized trials, women assigned to testosterone did not lose weight. If anything, the data leaned the other way: a small average increase in body weight compared with placebo, on the order of a fraction of a kilogram over the trial periods. It was statistically detectable and clinically minor, but it is the opposite of the viral promise.

The biological reasoning behind the claim is not absurd. Testosterone supports muscle protein synthesis, and in men with clinically low levels, replacement increases lean mass and modestly reduces fat mass. Women, though, are not small men. The amounts used in women’s trials aim for premenopausal physiological levels, a fraction of male concentrations, and at those levels the trials measured little change in body composition. Where lean mass did shift, the studies were short, small and not designed with weight as the goal.

Midlife weight gain has better-established drivers: a gradual fall in resting metabolic rate with age, loss of muscle from inactivity, sleep disruption, and a redistribution of fat toward the abdomen linked to falling estrogen. Resistance training, protein-adequate eating and treating sleep problems have consistent evidence for body composition in this age group. Testosterone does not.

A caution belongs here. Women who use amounts high enough to push levels above the female range can see changes in muscle and fat, along with acne, hair growth, voice changes and other effects that may not reverse. That is not testosterone therapy in the guideline sense; it is androgen excess, and the consensus statement warns against it.

The honest summary: on the evidence we have, testosterone will not make a woman lose weight, and a small gain is more likely than a loss. Anyone told otherwise should ask for the trial that shows it.

What are the side effects of testosterone therapy for women?

Side effects in the trials were mostly the ones you would predict from a hormone that acts on skin and hair, and they were dose-related.

Common and usually reversible. Acne and oily skin were the most frequent complaints, followed by increased hair growth on the face, chest or abdomen (hirsutism). In the pooled trial data, both occurred more often with testosterone than placebo, though most cases were mild. A small increase in weight, described above, also appeared. Local irritation at the application site occurred with gels and patches.

Less common and potentially permanent. Deepening of the voice, enlargement of the clitoris and male-pattern scalp hair loss are associated with levels above the female range. These were rare in trials that kept levels physiological, but they are the reason monitoring exists and the reason guidance is so insistent on not exceeding premenopausal concentrations. Once established, voice change in particular may not reverse.

Blood lipids. Oral testosterone lowered HDL (“good”) cholesterol in trials, which is why oral formulations are not recommended for women. Transdermal routes did not show this effect.

Serious events. Across the randomized trials, testosterone was not associated with an increase in serious adverse events, cardiovascular events or breast cancer during follow-up. That sentence needs its qualifier: follow-up rarely exceeded two years, participants were selected for good health, and women with prior breast cancer or high cardiovascular risk were excluded. “No signal in short trials” is reassuring but is not the same as “proven safe long term.”

Transfer. Gels and creams can transfer to a partner or child through skin contact until absorbed. Product guidance and clinicians give instructions on this; it is one reason application sites and hand-washing matter.

None of this makes testosterone unusually dangerous compared with other hormonal treatments. It makes it a medicine with a defined profile, best used with a clear indication, a plan to review, and an agreed point at which to stop.

Why won't doctors prescribe testosterone to women?

The question assumes a uniform refusal, and that is not quite what is happening. Some clinicians prescribe testosterone for postmenopausal HSDD readily; others decline. The reasons for hesitation are worth understanding because several are legitimate.

No approved product in the US. As of September 2026, the FDA has not approved any testosterone formulation for women. Prescribing therefore relies on products licensed for men, used at reduced amounts off-label, or on compounded preparations. Off-label prescribing is legal and common in medicine, but it places more responsibility on the clinician and requires a clear discussion of what is and is not known.

Compounded products. Compounding pharmacies prepare individualized preparations that are not FDA-approved and are not tested for consistency the way approved medicines are. The consensus statement recommends approved products where available and advises caution with compounded testosterone because delivered amounts can vary. This is a matter for the prescribing clinician; it is not a reason to seek such products independently.

Narrow evidence. A clinician asked to prescribe testosterone for fatigue, weight or memory is being asked to prescribe outside the evidence. Declining in that situation is not obstruction; it is the guideline position.

Diagnostic uncertainty. Because no blood level defines deficiency, some clinicians are uncomfortable treating without a measurable target. The consensus approach, treating the clinical syndrome and using levels only for safety monitoring, is not yet universal practice.

Training. Menopause care has historically received little curriculum time. Many clinicians did not train with testosterone as part of the toolkit and may be unaware that international guidance supports its use for one indication.

If your clinician declines, it is fair to ask why, and fair to ask for a referral to someone with menopause expertise. It is also fair for the clinician to say the evidence does not support the reason you are asking. Both conversations are part of good care.

Claims versus evidence: a summary table

Below is a compact scorecard. The evidence grade follows the tiers described earlier: randomized trials at the top, observational data in the middle, expert opinion or no data at the bottom.

Claim about testosterone for women	What trials show	Evidence grade	Guideline position (2019 consensus)
Improves sexual desire and satisfaction after menopause	Modest, consistent benefit across 36 randomized trials	Strong	Supported for HSDD after assessment of other causes
Improves libido before menopause	Very few trials, inconclusive	Insufficient	Not recommended
Boosts energy and reduces fatigue	No trial with fatigue as primary outcome; subscales mostly equal to placebo	Insufficient	Not recommended
Lifts mood or wellbeing	Small, short trials with mixed results	Weak	Not recommended
Sharpens memory or clears brain fog	Inconsistent observational data; no convincing trial benefit	Insufficient	Not recommended
Strengthens bone	Small density gains in two-year trials; no fracture data	Weak	Not recommended
Builds muscle or aids weight loss	No weight loss; small average weight gain in pooled trials	Insufficient (for benefit)	Not recommended
Safe long term	No serious-event signal within about two years; longer data absent	Unknown	Monitor; stop if no benefit at six months

A few observations from the table. Only one row earns a strong grade, and even that benefit is measured in roughly one additional satisfying sexual event per month. Every lifestyle-adjacent claim, the energy, the focus, the physique, sits in the insufficient tier, not because trials disproved them but because good trials were never done. That is an important distinction. “No evidence of benefit” and “evidence of no benefit” are different statements, and honesty requires keeping them apart while also declining to prescribe on hope.

The safety row is the one to keep in view. Short trials are reassuring, and the absence of long-term data is a genuine gap rather than a hidden danger. It argues for careful use, clear goals and regular review, not for panic and not for casual adoption.

Common myths about testosterone for women

Viral clips compress complicated science into confident sentences. Here are the sentences we hear most, and what the evidence says about each.

“Every woman over 40 is testosterone deficient.” Levels decline with age, but decline is not deficiency. No blood level defines deficiency in women, and most women with lower levels have no symptoms attributable to them. Treating a normal age-related change as a disease is not supported by any guideline.

“Menopause crashes your testosterone.” Natural menopause does not cause a sudden drop; estrogen falls sharply, testosterone drifts. The exception is surgical menopause, where removal of both ovaries roughly halves testosterone quickly.

“It will fix your fatigue and brain fog.” No randomized trial shows this. Sleep disruption from hot flashes, iron deficiency, thyroid disease and depression are far more likely explanations and have proven treatments.

“It melts fat and builds muscle.” Pooled trial data show a small weight gain, not a loss, at physiological amounts. Body composition changes appear only with levels above the female range, along with side effects that may not reverse.

“A quick blood test will tell you if you need it.” Assays are imprecise at female concentrations, levels vary through the day, and guidelines say the test should not be used to diagnose low desire. Its role is to exclude high levels and to monitor safety.

“Doctors withhold it because they are behind the times.” Some are unfamiliar with the evidence, but many decline because the request is for an unsupported indication or because no approved product exists in their country. Both are reasonable positions.

“Natural or compounded testosterone is safer.” Compounded preparations are not FDA-approved and vary in delivered amount. “Bioidentical” describes chemical structure, not safety, and approved transdermal products are also bioidentical testosterone.

“It is proven safe for life.” Trials rarely ran beyond two years. Short-term safety is reassuring; long-term safety is unstudied. Guidance therefore recommends periodic review and stopping when there is no benefit.

Who is, and is not, a candidate under current guidance?

Guidelines do not hand out eligibility like a checklist, but they do describe the woman for whom the evidence applies and the situations where it does not.

Where the evidence fits. A postmenopausal woman, whether by natural menopause or surgery, with a persistent loss of sexual desire that distresses her, in whom the clinician has assessed and addressed vaginal symptoms, mood, sleep, medications and relationship factors, and who understands that the expected benefit is modest and the long-term safety unknown. Many such women will already be using estrogen for menopausal symptoms; the consensus statement notes stronger evidence in that group, though benefit was also seen without estrogen.

Where the evidence is absent. Premenopausal women, for whom the consensus statement found insufficient data. Women seeking help for fatigue, mood, memory, weight or bone, for whom testosterone is not recommended. Women who have not yet had other causes of low desire explored.

Where caution is greatest. Women with a history of breast cancer, who were excluded from trials, so safety is unknown. Women with high cardiovascular risk, for the same reason. Women with existing acne, hirsutism or androgenic hair loss, who may find side effects intolerable. Women with a testosterone level already at the upper end of the female range, in whom treatment could push levels into excess.

What good use looks like. A baseline level before starting. A transdermal rather than oral product. A repeat level a few weeks in to confirm the female range has not been exceeded. A review at three to six months with a clear question: has desire and distress improved enough to justify continuing? Stopping if the answer is no. Periodic checks of skin, hair and levels for as long as treatment continues.

None of this is a recipe for self-management; the amounts, products and monitoring schedule are the prescribing clinician’s responsibility. It is a description of what the evidence-based version of this treatment involves, so that a woman can recognize it when she sees it, and recognize when what she is being offered is something else.

When to see a doctor

Two different situations bring women to this topic, and both deserve a clinician’s attention rather than an algorithm’s.

If you are considering testosterone. Book an appointment if low sexual desire has persisted for months and is causing you distress, particularly after menopause or after surgery to remove the ovaries. Bring a list of your medicines, including antidepressants and hormonal contraceptives, a note of your sleep pattern, and an honest account of mood and relationship factors. Ask what else could be causing the change, whether local estrogen might help if sex is uncomfortable, and, if testosterone is discussed, what benefit is realistic, how it will be monitored and when it would be stopped. If you have had breast cancer or have significant heart disease risk, say so early; it changes the conversation.

If you are already using testosterone. Contact your prescriber promptly, rather than waiting for a scheduled review, if you notice any of the following:

• Deepening or hoarseness of your voice
• New or rapidly increasing facial or body hair, or thinning of scalp hair
• Enlargement of the clitoris or persistent genital discomfort
• Severe or cystic acne
• Unexpected vaginal bleeding after menopause, which always warrants assessment
• A new breast lump or change, which requires evaluation regardless of hormone use
• Chest pain, sudden shortness of breath, or symptoms of a stroke, which need emergency care
• Marked mood change, irritability or aggression

Do not adjust the amount you use, switch products or stop abruptly on your own; discuss any change with the clinician who prescribed it. Do not obtain testosterone from online sellers or use a product prescribed for someone else. The safety record in trials depends on physiological levels and monitoring, and neither is guaranteed outside a supervised setting.

Finally, a note for anyone whose main complaint is fatigue, low mood or brain fog: those symptoms deserve their own assessment, including blood count, thyroid function and a conversation about sleep and mood. The evidence says testosterone is unlikely to be the answer, and a proper work-up may find one that is.

Frequently asked questions

What are the benefits of a female taking testosterone?

The one benefit demonstrated in randomized trials is improved sexual desire, arousal, orgasm and satisfaction in postmenopausal women with distressing low libido, with a modest average effect. Trials have not shown reliable benefits for energy, mood, memory, muscle, weight or bone. International guidance therefore supports testosterone for women only for postmenopausal hypoactive sexual desire disorder after other causes have been assessed, with the decision made by the prescribing clinician.

What are signs of low testosterone in females?

There is no validated symptom list, because no blood level defines low testosterone in women and the commonly cited features overlap with menopause, poor sleep, depression, iron deficiency and thyroid disease. Reduced sexual desire is the symptom most consistently linked to testosterone in research. Fatigue, low mood and brain fog usually have other, more likely causes. A clinician should assess the whole picture rather than attribute symptoms to one hormone.

Why won't doctors prescribe testosterone to women?

Several reasons: no FDA-approved product exists for women in the US, so prescribing is off-label; the evidence supports only one indication, distressing low desire after menopause; no blood level defines deficiency; and many clinicians received little menopause training. Declining to prescribe for fatigue or weight is consistent with guidelines. If you meet the evidence-based indication, asking for a referral to a clinician with menopause expertise is reasonable.

Will testosterone make a woman lose weight?

No. In pooled data from randomized trials, women taking testosterone showed a small average weight gain compared with placebo, not a loss. At the physiological amounts used for women, body composition changed little. Muscle and fat shifts appear mainly when levels exceed the female range, which brings side effects such as acne, hair growth and voice changes that may not reverse. Resistance training and sleep have far stronger evidence for midlife weight.

Is testosterone therapy for women safe long term?

Unknown. Randomized trials rarely lasted more than two years and found no increase in serious adverse events, heart problems or breast cancer within that window, but women with prior breast cancer or high cardiovascular risk were excluded. Guidelines describe this as reassuring short-term data with a genuine long-term gap, and recommend monitoring levels and stopping if there is no clear benefit after about six months.

How is low testosterone in women diagnosed?

It is not diagnosed by a number. The 2019 global consensus statement says blood testosterone should not be used to diagnose low sexual desire, because no cutoff distinguishes women with the condition from those without. The diagnosis is clinical, based on persistent low desire causing distress after other causes are excluded. A baseline level is taken mainly to rule out already-high levels and to allow safety monitoring during treatment.

Does testosterone help perimenopausal women?

The evidence is thin. Trials showing benefit for sexual desire were conducted in postmenopausal women, and the consensus statement found insufficient data to recommend testosterone for women still having menstrual cycles, including those in perimenopause. Two non-hormonal medicines are approved in the US for premenopausal low desire. Whether any treatment is appropriate during perimenopause is a decision for the treating clinician after a full assessment.

Can testosterone treat hot flashes or night sweats?

No. Hot flashes and night sweats are driven by falling estrogen, and estrogen-based hormone therapy and certain non-hormonal medicines are the treatments with trial evidence. Testosterone is not a treatment for vasomotor symptoms. In UK guidance it is considered only as an addition for low sexual desire when estrogen-based therapy alone has not helped, not as a substitute for it.

What are the side effects of testosterone in women?

The most common are acne, oily skin and increased facial or body hair, which are usually mild and reversible when levels stay in the female range. Less common effects linked to excess levels include voice deepening, clitoral enlargement and scalp hair loss, which may be permanent. Oral forms lower HDL cholesterol, so transdermal products are preferred. Gels can transfer to others through skin contact before absorption.

Is compounded testosterone for women approved or safe?

Compounded testosterone is not FDA-approved and is not tested for consistency the way approved medicines are, so delivered amounts can vary. The consensus statement recommends approved products where available and urges caution with compounded preparations. These are prescribing decisions for a clinician who can arrange monitoring; they are not products to seek out or use independently, and online sources should be avoided.

References

• Cleveland Clinic: Testosterone
• NHS: Types of hormone replacement therapy (HRT)
• MedlinePlus: Testosterone Levels Test

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.